Increase of number of shares and votes in Vicore Pharma
Stockholm, June 30, 2023 – Vicore Pharma Holding AB (publ) (“Vicore” or the “company”)’s registered share capital and number of shares and votes have increased during the month of June 2023.
As previously announced, the company’s board of directors resolved on directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share on June 9, 2023. Through the share issuances, Vicore receives issue proceeds of 500 MSEK before issue costs.
9,200,000 shares have been issued and registered with the Swedish Companies Registration Office in June 2023 based on the issue authorization granted by the annual general meeting on 11 May 2023. The remaining 20,675,000 shares were issued subject to the subsequent approval of an extraordinary general meeting and other customary placing conditions, including the approval and publication of a customary listing prospectus no later than seven business days after the extraordinary general meeting, which will be held on July 5, 2023.
As of today, the total number of registered shares and votes of Vicore amounts to 91,047,979. Furthermore, the registered share capital amounts to approximately SEK 45,523,989.06.
For further information, please contact:
Carl-Johan Dalsgaard, CEO, phone: +46 70 975 98 63, email@example.com
Hans Jeppsson, CFO, phone: +46 70 553 14 65, firstname.lastname@example.org
This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on June 30, 2023, at 09:00 CEST.
About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF. C21 is protected by US and European Orphan Designation. A variety of patents have been filed to provide further protection for C21, out to 2040 and onwards. Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. Using its unique expertise in the ATRAG biology Vicore is further fuelling its pipeline with several new small molecule drug assets, with long patent life and for a variety of indications, some of which could be partnered while others may be taken to the market by Vicore.
The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.